Compare Stocks: MIRA, RFAI, MIST, and RFL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MIRA MIRA Pharmaceuticals	$0.83 +9.6%	$0.80	$0.60 ▼ $2.45	$34.97M	1.52	1.60 million shs	682,603 shs
MIST Milestone Pharmaceuticals	$0.92 -0.4%	$1.13	$0.88 ▼ $3.06	$114.02M	0.98	1.47 million shs	562,522 shs
RFAI RF Acquisition Corp II	$39.81 -3.2%	$24.09	$8.94 ▼ $73.00	$142.26M	1.16	207,476 shs	6,233 shs
RFL Rafael	$2.06 -0.1%	$2.19	$1.12 ▼ $3.96	$106.60M	0.4	112,748 shs	361,465 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MIRA MIRA Pharmaceuticals	0.00%	+7.56%	+17.21%	-13.39%	-35.48%
MIST Milestone Pharmaceuticals	0.00%	-6.56%	-11.09%	-29.77%	-52.79%
RFAI RF Acquisition Corp II	0.00%	+32.27%	+212.74%	+261.43%	+274.35%
RFL Rafael	0.00%	-10.76%	+8.61%	-25.98%	+47.99%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MIRA MIRA Pharmaceuticals	$0.83 +9.6%	$0.80	$0.60 ▼ $2.45	$34.97M	1.52	1.60 million shs	682,603 shs
MIST Milestone Pharmaceuticals	$0.92 -0.4%	$1.13	$0.88 ▼ $3.06	$114.02M	0.98	1.47 million shs	562,522 shs
RFAI RF Acquisition Corp II	$39.81 -3.2%	$24.09	$8.94 ▼ $73.00	$142.26M	1.16	207,476 shs	6,233 shs
RFL Rafael	$2.06 -0.1%	$2.19	$1.12 ▼ $3.96	$106.60M	0.4	112,748 shs	361,465 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MIRA MIRA Pharmaceuticals	0.00%	+7.56%	+17.21%	-13.39%	-35.48%
MIST Milestone Pharmaceuticals	0.00%	-6.56%	-11.09%	-29.77%	-52.79%
RFAI RF Acquisition Corp II	0.00%	+32.27%	+212.74%	+261.43%	+274.35%
RFL Rafael	0.00%	-10.76%	+8.61%	-25.98%	+47.99%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MIRA MIRA Pharmaceuticals	2.33	Hold	$3.50	320.52% Upside
MIST Milestone Pharmaceuticals	2.71	Moderate Buy	$6.40	598.84% Upside
RFAI RF Acquisition Corp II	1.00	Sell	N/A	N/A
RFL Rafael	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest MIRA, RFAI, MIST, and RFL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/17/2026	MIRA MIRA Pharmaceuticals	Maxim Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$3.50
9/4/2026	RFAI RF Acquisition Corp II	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
9/3/2026	MIST Milestone Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/25/2026	RFL Rafael	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/21/2026	RFAI RF Acquisition Corp II	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D)
8/20/2026	MIRA MIRA Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/20/2026	MIST Milestone Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$3.00
8/7/2026	RFAI RF Acquisition Corp II	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C-)
8/6/2026	MIRA MIRA Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/14/2026	MIST Milestone Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/13/2026	MIST Milestone Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold

(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MIRA MIRA Pharmaceuticals	N/A	N/A	N/A	N/A	$0.25 per share	N/A
MIST Milestone Pharmaceuticals	$1.55M	73.56	N/A	N/A	$0.39 per share	2.35
RFAI RF Acquisition Corp II	N/A	N/A	N/A	N/A	N/A	N/A
RFL Rafael	$920K	116.27	N/A	N/A	$1.91 per share	1.08

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MIRA MIRA Pharmaceuticals	-$10.44M	-$1.24	N/A	N/A	N/A	N/A	-106.95%	-104.18%	12/2/2026 (Estimated)
MIST Milestone Pharmaceuticals	-$63.06M	-$0.69	N/A	N/A	N/A	N/A	-288.33%	-58.27%	11/11/2026 (Estimated)
RFAI RF Acquisition Corp II	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RFL Rafael	-$30.52M	-$0.68	N/A	N/A	N/A	-3,321.74%	-41.27%	-35.32%	10/28/2026 (Estimated)

Latest MIRA, RFAI, MIST, and RFL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	MIRA MIRA Pharmaceuticals	N/A	-$0.03	N/A	-$0.03	N/A	N/A
8/12/2026	Q2 2026	MIST Milestone Pharmaceuticals	-$0.1950	-$0.21	-$0.0150	-$0.21	$0.82 million	$0.56 million
8/7/2026	Q2 2026	RFAI RF Acquisition Corp II	N/A	$0.01	N/A	$0.01	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
MIRA MIRA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MIST Milestone Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RFAI RF Acquisition Corp II	N/A	N/A	N/A	N/A	N/A
RFL Rafael	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MIRA MIRA Pharmaceuticals	N/A	200.08	200.08
MIST Milestone Pharmaceuticals	3.25	8.13	7.92
RFAI RF Acquisition Corp II	N/A	N/A	N/A
RFL Rafael	N/A	3.16	3.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MIRA MIRA Pharmaceuticals	35.16%
MIST Milestone Pharmaceuticals	86.18%
RFAI RF Acquisition Corp II	N/A
RFL Rafael	11.30%

Insider Ownership

Company	Insider Ownership
MIRA MIRA Pharmaceuticals	19.89%
MIST Milestone Pharmaceuticals	5.03%
RFAI RF Acquisition Corp II	39.10%
RFL Rafael	32.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MIRA MIRA Pharmaceuticals	2	42.02 million	33.66 million	Not Optionable
MIST Milestone Pharmaceuticals	38	124.50 million	118.24 million	Optionable
RFAI RF Acquisition Corp II	2	3.51 million	2.14 million	N/A
RFL Rafael	23	52.00 million	34.89 million	Optionable

MIRA, RFAI, MIST, and RFL Headlines

Recent News About These Companies

ANI Pharmaceuticals (NASDAQ:ANIP) & Rafael (NYSE:RFL) Head to Head Contrast

September 15, 2026 | americanbankingnews.com

Rafael Holdings Inc Share Price (RFL.US)

July 15, 2026 | lse.co.uk

Rafael Holdings Insider Trading Activity | NYSE:RFL | Benzinga

July 2, 2026 | benzinga.com

Rafael Holdings: The Second Half Of Calendar 2026 Could Define This Company Forever

June 29, 2026 | seekingalpha.com

Rafael Holdings (NYSE:RFL) Stock, Short Interest Report

June 25, 2026 | benzinga.com

Rafael Holdings (NYSE: RFL) - Share Price and Research

June 25, 2026 | intelligentinvestor.com.auI

Rafael B Stock Price History

June 11, 2026 | investing.com

Rafael Holdings, Inc. Reports Q3 Fiscal 2026 Financial Results and Progress on Phase 3 TransportNPC™ Trial

June 11, 2026 | quiverquant.comQ

Rafael Holdings Reports Third Quarter Fiscal 2026 Financial Results

June 11, 2026 | globenewswire.com

Rafael Holdings Announces Completion of Last Patient Last Visit for Pivotal Phase 3 TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick ...

June 10, 2026 | finance.yahoo.com

Rafael Holdings Announces Completion of Last Patient Last Visit for Pivotal Phase 3 TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C

June 10, 2026 | globenewswire.com

Rafael Holdings Insider Ups Holding By 1,810% During Year

April 28, 2026 | finance.yahoo.com

Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve ...

April 22, 2026 | caledonianrecord.comC

Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve Myelination in ApoE4 positive Alzheimer’s Disease”

April 22, 2026 | markets.businessinsider.com

Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve Myelination in ApoE4 positive Alzheimer's Disease”

April 22, 2026 | globenewswire.com

Rafael Holdings Inc. Wt

April 4, 2026 | barrons.com

Rafael Holdings, Inc.: Rafael Holdings Reports Second Quarter Fiscal 2026 Financial Results

March 17, 2026 | finanznachrichten.de

Rafael Holdings Reports Second Quarter Fiscal 2026 Financial Results

March 16, 2026 | globenewswire.com

Rafael Holdings (NYSE:RFL) Short Interest Falls on NYSE Composite

March 1, 2026 | kalkinemedia.comK

Rafael Deepens Space Focus As IPO Decision Looms

February 4, 2026 | aviationweek.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

MIRA, RFAI, MIST, and RFL Company Descriptions

MIRA Pharmaceuticals NASDAQ:MIRA

$0.83 +0.07 (+9.61%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$0.80 -0.03 (-3.28%)

As of 09/18/2026 07:52 PM Eastern

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.

Milestone Pharmaceuticals NASDAQ:MIST

$0.92 0.00 (-0.41%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$0.92 +0.00 (+0.46%)

As of 09/18/2026 07:50 PM Eastern

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

RF Acquisition Corp II NASDAQ:RFAI

$39.81 -1.31 (-3.18%)

Closing price 09/18/2026 03:59 PM Eastern

Extended Trading

$40.10 +0.29 (+0.72%)

As of 09/18/2026 07:30 PM Eastern

RF Acquisition Corp. II operates as a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 5, 2024, and is headquartered in Singapore.

Rafael NYSE:RFL

$2.06 0.00 (-0.15%)

Closing price 09/18/2026 03:59 PM Eastern

Extended Trading

$2.06 0.00 (-0.10%)

As of 09/18/2026 07:30 PM Eastern

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1B clinical studies; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrumentation. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MIRA, RFAI, MIST, and RFL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MIRA, RFAI, MIST, and RFL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MIRA, RFAI, MIST, and RFL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MIRA, RFAI, MIST, and RFL Company Descriptions

MIRA Pharmaceuticals NASDAQ:MIRA

Milestone Pharmaceuticals NASDAQ:MIST

RF Acquisition Corp II NASDAQ:RFAI

Rafael NYSE:RFL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MIRA, RFAI, MIST, and RFL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MIRA, RFAI, MIST, and RFL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MIRA, RFAI, MIST, and RFL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MIRA, RFAI, MIST, and RFL Company Descriptions

MIRA Pharmaceuticals NASDAQ:MIRA

Milestone Pharmaceuticals NASDAQ:MIST

RF Acquisition Corp II NASDAQ:RFAI

Rafael NYSE:RFL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools